Pharma BD Deal Intelligence

Viatris / Pacira BioSciences, Inc.

2026 · Acquisition/Merger · $1.6B · Pending

On October 8, 2026 Viatris Inc. agreed to acquire all outstanding shares of Pacira BioSciences, Inc. for $36.50 per share in cash, implying a transaction value of approximately $1.65 billion. The deal is structured as a cash tender offer followed by a merger, with the tender offer to begin within 15 business days of signing. Pacira brings two patent-protected, in-market U.S. products -- EXPAREL (bupivacaine liposome injectable suspension) and ZILRETTA (triamcinolone acetonide extended-release injectable suspension) -- plus the iovera cryoanalgesia device, positioning Viatris as a leader in non-opioid pain therapies. The transaction is expected to close by the end of 2026, after which Pacira becomes a wholly owned Viatris subsidiary and is delisted from Nasdaq.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals